FDA Set to Regulate LDTs - Citing Safety Concerns and Advanced Technologies

by Foley & Lardner LLP

Advances in medical technology have increased the use of diagnostic tests to guide therapeutic decisions for many diseases and conditions, especially in the context of personalized medicine. Citing the need to ensure that certain tests used by health care professionals that diagnose and treat patients are accurate, consistent and reliable, the U.S. Food and Drug Administration (FDA) signaled that the Agency is lifting its enforcement discretion over certain laboratory developed tests (LDTs) that aid physicians in selecting appropriate therapies for patients. “Anticipated Details of the Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” (Guidance) provides anticipated details of a draft guidance to be issued no earlier than 60 days from the July 31, 2014 publication of the Guidance, and fulfills the agency’s requirement to notify Congress of its intent to publish the draft guidance consistent with the Food and Drug Administration Safety and Innovation Act of 2012.

The Guidance proposes a risk-based, phased-in framework for oversight of LDTs that is in accordance with FDAs current regulation of in vitro diagnostic devices (IVDs).

The Need for Increased Regulatory Oversight of LDTs

In support of increased regulatory oversight, the FDA makes note of the evolution of LDT technology, marketing and business models. Historically, LDTs were manufactured in small volumes by local laboratories. These tests were used and interpreted directly by physicians and pathologists working within a single institution. In addition, traditional LDTs were manufactured using components that were legally marketed for clinical use. More recently, LDTs are manufactured with components and instruments that are not legally marketed for clinical use and rely heavily on high-tech instrumentation and software to generate results and clinical interpretations.

The FDA also noted that business models have changed. For example, overnight shipping and electronic delivery of information makes it possible, and not uncommon, for a single laboratory to provide device results nationally and internationally. Moreover, many new LDTs manufacturers are large corporations that nationally market a limited number of complex, high-risk devices.

Noting the changes in the complexity and use of LDTs, the FDA believes that the policy of general enforcement discretion towards LDTs is no longer appropriate, and that historical oversight by the Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) regulations are deficient in several aspects. They are noted to fail to:

  • Adequately assure the safety and effectiveness of LDTs;
  • Require adverse event reporting, making it difficult for regulators to detect devices that are inaccurate, ineffective or unsafe;
  • Require the removal of unsafe devices from the market;
  • Assess the quality manufacturing of devices; and
  • Require informed consent for patients who participate in LDT clinical studies or establish procedures for the conduct of such studies.

Most importantly, the Agency notes serious concerns regarding the lack of independent review of clinical validity of LDTs. Clinical validity is defined as the ability of a diagnostic device to measure or detect the clinical condition for which the device is intended. LDTs, it is noted, have not been properly clinical validated for risk of missed or incorrect diagnosis, failure to administer appropriate treatment or administration of potentially harmful treatments with no benefit. Guidance at page 8.

Risk-Based Approach and Timelines

The Guidance indicates that the FDA will rely upon the existing medical device classification system to evaluate the risk category of LDTs and will use expert advisory panels to help classify devices not previously classified by the FDA. The Guidance indicates that the FDA will continue to exercise enforcement discretion over two specified tests – tests used solely for forensic or law enforcement purposes and those used for transplantation, when used in CLIA-certified, high complexity histocompatibility laboratories.

For those defined as low-risk LDTs (e.g., Class I devices), the FDA indicated that it will continue to exercise its discretion with respect to applicable premarket review requirements and quality system requirements, but will enforce other applicable regulatory requirements and adverse event reporting.

For the remaining LDTs, such as high and moderate risk LDTs, the FDA indicated an intention to enforce applicable regulatory requirements including registration and listing, adverse event reporting and premarket reporting. Enforcement will commence six months after the finalization of the draft guidance. Premarket review requirements are to begin 12 months after finalization for the highest risk devices and will be phased-in over 4 years for the remaining high-risk devices. However, high-risk devices may remain on the market during review and FDAs considerations of applications.

High-Risk Companion Diagnostics

Diagnostic tests that match therapies with patients are key to personalized medicine. Due to the clinical importance and relevance of these tests, the Guidance signals with certainty FDAs intention to regulate these tests consistent with IVDs. Undoubtedly, the FDAs impending oversight of these tests will be controversial due to the increased cost of compliance for these previously unregulated tests. However, many in the forefront of personalized medicine would disagree. Dr. Francis Collins, speaking on behalf of the NIH, noted that the “NIH supports our sister agency’s proposal and thinks that this thoughtful framework which focuses greatest attention on tests with the most significant clinical impact will protect public health, without putting a damper on biomedical innovation or placing an undue burden on the industry.” (Remarks at “Statement on FDA’s Proposed Oversight of Laboratory-Developed Tests”, July 31, 2014.)

View This Blog

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.